Clinical Trial Update: Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With Venetoclax [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating pirtobrutinib (LOXO-305) as consolidation to eradicate minimal residual disease in chronic lymphocytic leukemia/small lymphocytic l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Pirtobrutinib (pirtobrutinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1, Phase 2 | Status: TERMINATED